4.7 Article

Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model

Journal

CLINICAL IMMUNOLOGY
Volume 149, Issue 3, Pages 487-497

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2013.10.004

Keywords

Chikungunya virus; Monoclonal antibodies; Disease protection; ELISA; Immunohistochemistry; Diagnostic

Categories

Funding

  1. University of Queensland international research tuition award (UQIRTA) from UQ Graduate Schooll, The University of Queensland
  2. ANZ Trustees Scholarship for Medical Research, Queensland

Ask authors/readers for more resources

Chikungunya virus (CHIKV) recently caused the largest epidemic ever recorded for this virus involving an estimated 1.4-6.5 million cases, with imported cased reported in over 40 countries. The number of monoclonal antibodies specific for this re-emerging alphavirus is currently limited. Herein we describe the generation and characterisation of five monoclonal antibodies specific for the E2 glycoprotein of CHIKV. The antibodies detected a range of CHIKV isolates in several assays including ELISA, Western blot, immunofluorescence assay (IFA) and immunohistochemistry (IHC) without evidence of cross-reactivity with other alphaviruses. Four antibodies also neutralised CHIKV in vitro, two of which provided complete protection against arthritis in a CHIKV mouse model when administered prior to infection. Given the current shortage of widely available reagents for CHIKV, these specific antibodies will be useful not only in research, but may also provide the basis for new diagnostics and treatments. (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available